Form D · Biotechnology
Pathway Therapeutics, Inc.
San Francisco, CA · CIK 0001498495
Offering snapshot reported Mar 6, 2013 · SEC filing
- Reported sold
- $400K Offering amount: $750K
- Investors reported
- 3 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Feb 21, 2013 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Mar 6, 2013 | Initial | $400,000 | No comparison | 3 | SEC filing |
| Nov 30, 2012 | Initial | $200,000 | No comparison | 4 | SEC filing |
| Jun 7, 2011 | Initial | $7,500,000 | No comparison | 4 | SEC filing |
| Aug 10, 2010 | Initial | $8,751,046 | No comparison | 6 | SEC filing |
Offering details
- Securities
- Debt, Option to acquire, Security to be acquired
- Exemptions
- 06
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-192819
Source: Form D, filed Mar 6, 2013. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Will Charles | Director |
| Julie Cherrington | Director, Executive |
| Joshua Funder | Director |
| Paul Goddard | Director |
| Mark Harvey | Director |
| Carrie Hillyard | Director |
| Hilary Lewis | Director |
| Hillary Lewis | Director |
| Mark Perry | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
409 Illinois Street
San Francisco, CA, 94158
San Francisco, CA, 94158